介素-1受体关联激酶-1是胃癌的治疗点
Hui Shi1, Jie Zhang1, Xiaohua Bao2
1Department of Gastroenterology, The 964th Hospital of People's Liberation Army Joint Logistic Support Force, No. 4799 Xi'an Road, Changchun, P.R. China.
Discover oncology
|October 14, 2025
概括
介素-1受体相关激酶1 (IRAK1) 驱动胃癌的生长. 在临床前模型中,用pacritinib抑制IRAK1有效地抑制了瘤的进展,这表明IRAK1是胃癌的治疗标.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 介素-1受体相关激酶1 (IRAK1) 在先天免疫和炎症中至关重要.
- 在多种癌症类型中观察到IRAK1的构成性激活.
- 在胃癌进展中IRAK1的作用需要进一步阐明.
研究的目的:
- 研究IRAK1在胃癌中的作用.
- 评估向IRAK1在胃癌中的治疗潜力.
主要方法:
- 在胃癌组织和细胞中IRAK1表达的分析.
- 在体外研究涉及IRAK1过度表达和胃癌细胞中的遗传沉默.
- 对IRAK1/4抑制剂,帕克里提尼布和托法西提尼布的药物敏感性的评估.
- 在体内异种移植小鼠模型实验中评估帕克里替尼的疗效.
- 免疫组织化学分析以确认药物诱导的IRAK1抑制.
主要成果:
- 在胃癌组织和细胞中发现IRAK1表达升高,与增加的增殖,殖民地形成和迁移相关.
- IRAK1的过度表达增强了恶性表型,而其遗传沉默则抑制了这些特征.
- 胃癌细胞对帕克里替尼 (IRAK1/JAK2抑制剂) 的敏感性比托法西替尼 (泛-JAK抑制剂) 高.
- 帕克里蒂尼布在体内有效抑制胃癌的生长,没有显著的毒性,并降低了瘤中的IRAK1活性.
结论:
- 伊拉克1在促进胃癌进展方面发挥着重要作用.
- 伊拉克1是胃癌治疗的有前途的治疗标.
- 由于其IRAK1抑制活性,帕克里提尼布在胃癌治疗中显示出重新利用的潜力.
更多相关视频
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
2.5K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
511
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
511
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
01:20The JAK-STAT Signaling Pathway
11.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.7K
01:22PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K